Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | UNG | P13051 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28063166 | 0.86 | HSD17B10 (0.59) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL20306075 | 0.84 | GAA (0.46) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL5315788 | 0.83 | CYP1A2 (0.56) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL3934082 | 0.81 | CYP1A2 (0.63) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL4250794 | 0.81 | LOXL2 (0.49) | HSD17B10HPGDFOLH1CA12CA1 | |
| SCHEMBL11941050 | 0.80 | TPMT (0.43) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL6526151 | 0.79 | CYP1A2 (0.59) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL659462 | 0.79 | HSD17B10 (0.70) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL29664414 | 0.79 | HSD17B10 (0.70) | HSD17B10CYP1A2CYP2C9HPGDAPEX1 | |
| SCHEMBL13859440 | 0.78 | ABL1 (0.44) | HSD17B10CYP1A2CYP2C9HPGDMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346604-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS | 2025-11-13 | — | — | US | disclosed |
| US-20250235453-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS | 2025-07-24 | — | — | US | disclosed |
| WO-2024091473-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023076259-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | HSD17B10 1370/4885CYP1A2 3256/4885CYP2C9 4435/4885 |
| US-20250346604-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | RAC1, TNK2, GDI2 | HSD17B10 4257/4885CYP1A2 3126/4885CYP2C9 1730/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | HSD17B10 1675/4885CYP1A2 1673/4885CYP2C9 2947/4885 |
| US-20250235453-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | RAC1, TNK2, GDI2 | HSD17B10 4257/4885CYP1A2 3126/4885CYP2C9 1730/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | HSD17B10 1675/4885CYP1A2 1673/4885CYP2C9 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.